Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
OsteoDex, the company's phase 2b study for the treatment of advanced prostate cancer, so-called castration-resistant metastatic prostate cancer (mCRPC), will have complete follow-up for all patients at the end of April 2020, which concludes the phase II study. The results will be reported in May 2020. Interim results at today's date are still very promising with significantly longer survival for patients who responded to treatment compared to the other patients. A handful of big pharma companies interested in OsteoDex have announced that they want to wait for the final results for patients' survival, which will be reported to them in May 2020.
DexTech's goal is to sign a license agreement regarding OsteoDex before the end of 2020.
The treatment of mCRPC has as a fundamental goal to be life-prolonging and preferably with acceptable side effects.
"- We have full understanding that our interested parties want to see the final result of the follow up. I think we have very good possibilities to achieve the ultimate goal with the OsteoDex treatment," says CEO Anders R Holmberg.
For additional information:
Gösta Lundgren - CFO & Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
E-mail: gosta.lundgren@dextechmedical.com
This information is information that Dextech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on February 18, 2020.